Related Experiment Video
Updated: May 5, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
An ISHLT consensus statement on strategies to prevent and manage hemocompatibility related adverse events in patients
Ian B Hollis1, Douglas L Jennings2, Selim Krim3
1University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina; University of North Carolina Medical Center, Chapel Hill, North Carolina.
Abstract:
Life expectancy of patients with a durable, continuous-flow left ventricular assist device (CF-LVAD) continues to increase. Despite significant improvements in the delivery of care for patients with these devices, hemocompatability-related adverse events (HRAEs) are still a concern and contribute to significant morbility and mortality when they occur. As such, dissemination of current best evidence and practices is of critical importance. This ISHLT Consensus Statement is a summative assessment of the current literature on prevention and management of HRAEs through optimal management of oral anticoagulant and antiplatelet medications, parenteral anticoagulant medications, management of patients at high risk for HRAEs and those experiencing thrombotic or bleeding events, and device management outside of antithrombotic medications. This document is intended to assist clinicians caring for patients with a CF-LVAD provide the best care possible with respect to prevention and management of these events.
Related Concept Videos
Cardiac Catheterization IV: Nursing Management
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Hemodialysis II: Procedure and Complications

